NL-OMON37271已完成不适用
Evaluation of VEGF expression with 89Zr-bevacizumab PET scan in patients with relapsing multiple myeloma; a feasibility study. - 89Zr-bevacizumab PET MM
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with relapsing multiple myeloma according to international defined guidelines:;Relapse after having achieved complete remission:
- •1. Reappearance of paraprotein
- •2. More than 5% plasma cells in bone marrow.
- •3. New lytic lesions or progression of old lesions.
- •4. New hypercalceamia.;Relapse after having achieved partial remsission
- •1. Increases of paraprotein with more than 25%
- •2. Increase of urine paraprotein with more than 25%
- •3. Increase of plasma cells in bone marrow with 10%
- •4. New lytic lesions or progression of old lesions
- •5. New hypercalceamia
排除标准
- •- Radiotherapy in the last 3 months.
- •- Ineligible to lay supine during the PET scan.
- •- Age <=18 years.
- •- Pregnancy.
- •- Claustrophobia
- •- Severe kidney dysfunction; serum-creatinine >=250 µM
研究者
相似试验
进行中（未招募）
不适用
Evaluation of protein expression with labeled-bevacizumab scan in patients with relapsing multiple myeloma.EUCTR2012-002335-28-NLniversity medical centre groningen20
Unknown
不适用
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple MyelomaMultiple MyelomaNCT01859234University Medical Center Groningen20
尚未招募
不适用
Radiolabeled bevacizumab as a tracer of VEGF expression in patients with colorectal liver metastasescolorectal liver metastases10027476NL-OMON29757niversitair Medisch Centrum Sint Radboud10
已完成
不适用
Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell CarcinomaMetastatic Renal Cell CarcinomaNCT01028638University Medical Center Groningen13
尚未招募
2 期
Identification of biological effects of bevacizumab in surgically resectable melanoma tumors.melanoma cancer10040900skin cancerNL-OMON30987niversitair Medisch Centrum Groningen10